Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center in Buffalo, NY, shares a brief overview of AML and discusses how the treatment landscape for patients with AML has changed in recent years.
Click here to learn more.
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
